Product information
For almost a century, Bayer has been working to make a positive difference to women’s health through pioneering research and innovation.
In the 1920s, Bayer—then called Schering AG—made a significant contribution to understanding the molecular structure of sex hormones and launched the world's first oestrogen preparation for menopause management. This firmly set Bayer as a pioneer in women’s healthcare and, in 1961, Bayer became the first company to launch a contraceptive pill in Europe, the combined oral contraceptive Anovlar® (norethisterone acetate/ethinylestradiol)1. Anovlar is no longer produced.
More recent innovations include the introduction of Kyleena® (19.5 mg intrauterine delivery system levonorgestrel) a low-dose, levonorgestrel-releasing intrauterine delivery system which was launched in the UK in 2018.2
- Pletzer BA and Kerschbaum HH. Front Neurosci 2014;8:256. Return to content
- Kyleena® Prescribing information. Available from: https://www.whmatters.co.uk/kyleena-prescribing-information Last accessed: January 2022 Return to content
Just like you, we care about women’s health…
In the 1960s, we were one of the first to launch the contraceptive pill in Europe, giving women more power to choose their own future. Today, we continue to work with women and their clinicians to understand what really matters and where our expertise can help.
You’re a lifelong learner.
So are we.
Whether you want to master new procedures or join the conversation driving innovation in women’s health, we can help.
You care about delivering the best care. So do we.
We’re always looking for ways to help you to help your patients.
Bayer’s innovations in women’s health timeline:
1960
First European birth control pill, the combined oral contraceptive Anovlar® (norethisterone/ethinylestradiol). Anovlar is no longer produced.
Progestogen-only pill (mini-pill)
Progestogen-only emergency contraception, launched in the UK
Low-estrogen dose contraceptive pill
First pill to treat premenstrual dysphoric disorder, a severe form of premenstrual syndrome, in the US for women who choose the contraceptive pill for birth control
Jaydess®▼ (13.5 mg intrauterine delivery system levonorgestrel) was launched in 2014
First birth control pill approved for the treatment of heavy menstrual bleeding, Qlaira®
Kyleena® (19.5 mg intrauterine delivery system levonorgestrel), a low-dose levonorgestrel-releasing IUS was launched in the UK in 2018
Present day
- Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling. Int J Womens Health. 2016;8:589–598. Published 2016 Oct 13. doi:10.2147/IJWH.S99705 Return to content
- Bayer Plc. Qlaira®, film-coated tablets: Summary of Product Characteristics [online]. Updated 17 December 2018. Available from: https://www.medicines.org.uk/emc/product/6536 [Last accessed: January 2022]. Return to content
Bayer offers a number of contraception methods for women, depending on their personal needs. These include:
Qlaira®
(estradiol valerate / dienogest)
is a combined oral contraceptive approved for the treatment of menorrhagia1. The decision to prescribe Qlaira should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Qlaira compares with other combined hormonal contraceptives.
- Bayer Plc. Qlaira® (estradiol valerate/dienogest): Summary of Product Characteristics [online]. Updated 27 December 2018]. Available from: https://www.medicines.org.uk/emc/product/6536/smpc [Last accessed: January 2022]. Return to content
- Bayer Plc. Mirena® (52 mg intrauterine delivery system levonorgestrel): Summary of Product Characteristics [online]. Updated January 2022. Available from: https://www.medicines.org.uk/emc/product/1132 [Last accessed: January 2022]. Return to content
- Bayer Plc. Kyleena® (19.5 mg intrauterine delivery system levonorgestrel): Summary of Product Characteristics [online]. Updated 31 December 2021. Available from: https://www.medicines.org.uk/emc/product/769 [Last accessed: January 2022]. Return to content
Recommendations
Reporting adverse events and quality complaints
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: pvuk@bayer.com
Further information is available on the “contact” tab at www.bayer.co.uk.
